Skip to main content

Market Overview

UPDATE: Mizuho Securities USA Initiates Coverage On Epizyme Inc On Epigenetics Pure Play

Share:

In a report published Friday, Mizuho Securities USA analyst Peter Lawson initiated coverage on Epizyme Inc (NASDAQ: EPZM) with a Buy rating and $35.00 price target.

In the report, Mizuho Securities USA noted, “We are initiating coverage of shares of Epizyme with a Buy rating and a price target of $35. Epizyme is a pure-play on epigenetics, a gene regulatory system that can be exploited to target cancer cells. While the company's pipeline is early phase, valuation is supported by a series of significant biopharmaceutical partners, a series of 4Q14 Phase I readouts, and a platform and IP for further discovery.”

Epizyme closed on Thursday at $28.20.

Latest Ratings for EPZM

DateFirmActionFromTo
Mar 2022HC Wainwright & Co.MaintainsBuy
Aug 2021Morgan StanleyDowngradesEqual-WeightUnderweight
Aug 2021HC Wainwright & Co.MaintainsBuy

View More Analyst Ratings for EPZM

View the Latest Analyst Ratings

 

Related Articles (EPZM)

View Comments and Join the Discussion!

Posted-In: Mizuho Securities USA Peter LawsonAnalyst Color Initiation Analyst Ratings

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com